162 related articles for article (PubMed ID: 14738486)
1. Vigabatrin-associated loss of vision: rarebit perimetry illuminates the dose-damage relationship.
Frisén L
Acta Ophthalmol Scand; 2004 Feb; 82(1):54-8. PubMed ID: 14738486
[TBL] [Abstract][Full Text] [Related]
2. [Vigabatrin and visual field defects. A Danish material with evaluation of different screening methods].
Riise P; Fledelius HC; Rogvi-Hansen Bà
Ugeskr Laeger; 2003 Mar; 165(10):1034-8. PubMed ID: 12645411
[TBL] [Abstract][Full Text] [Related]
3. Vigabatrin-associated visual field constriction in a longitudinal series. Reversibility suggested after drug withdrawal.
Fledelius HC
Acta Ophthalmol Scand; 2003 Feb; 81(1):41-6. PubMed ID: 12631018
[TBL] [Abstract][Full Text] [Related]
4. Vigabatrin visual toxicity: evolution and dose dependence.
Malmgren K; Ben-Menachem E; Frisén L
Epilepsia; 2001 May; 42(5):609-15. PubMed ID: 11380567
[TBL] [Abstract][Full Text] [Related]
5. Visual field severity indices demonstrate dose-dependent visual loss from vigabatrin therapy.
Conway M; Cubbidge RP; Hosking SL
Epilepsia; 2008 Jan; 49(1):108-16. PubMed ID: 18184224
[TBL] [Abstract][Full Text] [Related]
6. Visual field loss in patients with refractory partial epilepsy treated with vigabatrin: final results from an open-label, observational, multicentre study.
Wild JM; Chiron C; Ahn H; Baulac M; Bursztyn J; Gandolfo E; Goldberg I; Goñi FJ; Mercier F; Nordmann JP; Safran AB; Schiefer U; Perucca E
CNS Drugs; 2009 Nov; 23(11):965-82. PubMed ID: 19845417
[TBL] [Abstract][Full Text] [Related]
7. The Topographical Relationship between Visual Field Loss and Peripapillary Retinal Nerve Fibre Layer Thinning Arising from Long-Term Exposure to Vigabatrin.
Wild JM; Aljarudi S; Smith PEM; Knupp C
CNS Drugs; 2019 Feb; 33(2):161-173. PubMed ID: 30637668
[TBL] [Abstract][Full Text] [Related]
8. Modelling the topography of absolute defects in patients exposed to the anti-epileptic drug vigabatrin and in normal subjects using automated static suprathreshold perimetry of the entire 80° visual field.
Besch D; Schiefer U; Eter N; Burth R; Elger CE; Spitznas M; Dietz K
Graefes Arch Clin Exp Ophthalmol; 2011 Sep; 249(9):1333-43. PubMed ID: 21380539
[TBL] [Abstract][Full Text] [Related]
9. Nasal retinal nerve fiber layer attenuation: a biomarker for vigabatrin toxicity.
Lawthom C; Smith PE; Wild JM
Ophthalmology; 2009 Mar; 116(3):565-71. PubMed ID: 19168223
[TBL] [Abstract][Full Text] [Related]
10. Vigabatrin associated visual field loss: a clinical audit to study prevalence, drug history and effects of drug withdrawal.
Newman WD; Tocher K; Acheson JF
Eye (Lond); 2002 Sep; 16(5):567-71. PubMed ID: 12194070
[TBL] [Abstract][Full Text] [Related]
11. [Changes in visual field of a child treatment with vigabatrin for 2 years].
Mrugacz M; Bakunowicz-Łazarczyk A
Klin Oczna; 2003; 105(5):313-4. PubMed ID: 14746187
[TBL] [Abstract][Full Text] [Related]
12. Vigabatrin-induced peripheral visual field defects in patients with refractory partial epilepsy.
Sergott RC; Bittman RM; Christen EM; Sagar SM
Epilepsy Res; 2010 Dec; 92(2-3):170-6. PubMed ID: 20951555
[TBL] [Abstract][Full Text] [Related]
13. Detecting vigabatrin toxicity by imaging of the retinal nerve fiber layer.
Wild JM; Robson CR; Jones AL; Cunliffe IA; Smith PE
Invest Ophthalmol Vis Sci; 2006 Mar; 47(3):917-24. PubMed ID: 16505024
[TBL] [Abstract][Full Text] [Related]
14. Visual field loss associated with vigabatrin: quantification and relation to dosage.
Hardus P; Verduin WM; Engelsman M; Edelbroek PM; Segers JP; Berendschot TT; Stilma JS
Epilepsia; 2001 Feb; 42(2):262-7. PubMed ID: 11240600
[TBL] [Abstract][Full Text] [Related]
15. Does vigabatrin treatment for infantile spasms cause visual field defects? An international multicentre study.
Riikonen R; Rener-Primec Z; Carmant L; Dorofeeva M; Hollody K; Szabo I; Krajnc BS; Wohlrab G; Sorri I
Dev Med Child Neurol; 2015 Jan; 57(1):60-7. PubMed ID: 25145415
[TBL] [Abstract][Full Text] [Related]
16. Concentric contraction of the visual field in patients with temporal lobe epilepsy and its association with the use of vigabatrin medication.
Hardus P; Verduin WM; Postma G; Stilma JS; Berendschot TT; van Veelen CW
Epilepsia; 2000 May; 41(5):581-7. PubMed ID: 10802764
[TBL] [Abstract][Full Text] [Related]
17. Examining visual field defects in the paediatric population exposed to vigabatrin.
Spencer EL; Harding GF
Doc Ophthalmol; 2003 Nov; 107(3):281-7. PubMed ID: 14711160
[TBL] [Abstract][Full Text] [Related]
18. Patterns of peripapillary retinal nerve fiber layer thinning in vigabatrin-exposed individuals.
Clayton LM; Devile M; Punte T; de Haan GJ; Sander JW; Acheson JF; Sisodiya SM
Ophthalmology; 2012 Oct; 119(10):2152-60. PubMed ID: 22853973
[TBL] [Abstract][Full Text] [Related]
19. Visual function is stable in patients who continue long-term vigabatrin therapy: implications for clinical decision making.
Paul SR; Krauss GL; Miller NR; Medura MT; Miller TA; Johnson MA
Epilepsia; 2001 Apr; 42(4):525-30. PubMed ID: 11440348
[TBL] [Abstract][Full Text] [Related]
20. Visual field defects in patients taking vigabatrin.
Midelfart A; Midelfart E; Brodtkorb E
Acta Ophthalmol Scand; 2000 Oct; 78(5):580-4. PubMed ID: 11037919
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
